Oxford BioDynamicsOXBOF Receivables Turnover is 1.88 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Oxford BioDynamics ranks worse than 85.22% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Oxford BioDynamics's Revenue for the
six
months ended in Mar. 2026 was $0.92 Mil. Oxford BioDynamics's average Accounts Receivable for the
six
months ended in Mar. 2026 was $0.49 Mil.
Hence, Oxford BioDynamics's Receivables Turnover for the
six
months ended in Mar. 2026 was 1.88.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Oxford BioDynamics Receivables Turnover Related Terms
Oxford BioDynamics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Oxford BioDynamics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OXBOF vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Oxford BioDynamics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioDynamics Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Oxford BioDynamics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioDynamics (OXBOF) has a Receivables Turnover of 1.88 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oxford BioDynamics and its competitors. According to the industry distribution chart, Oxford BioDynamics ranks #173 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 85.2%.
Is Oxford BioDynamics' Receivables Turnover too high?
Oxford BioDynamics' current Receivables Turnover is 1.88. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. Oxford BioDynamics' value of 1.88 is 65.1% below this industry median. Based on the distribution chart, Oxford BioDynamics ranks #173 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Oxford BioDynamics' Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #173 out of 203 companies for Receivables Turnover. This places Oxford BioDynamics in the lower half of its industry. The industry median Receivables Turnover is 5.39. Oxford BioDynamics' value of 1.88 is 65.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioDynamics's current Receivables Turnover of 1.88 is 65.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oxford BioDynamics and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioDynamics's current Receivables Turnover is 1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 75% below its estimated fair value. The current Receivables Turnover is 1.88 and 65.1% below the Medical Diagnostics & Research industry median of 5.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current Receivables Turnover is 1.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBOF has been successfully added to your 